ReviewJournal of clinical medicine2025
Global Trends in ADHD Medication Use: Multiple Contexts and Rising Concerns-A Narrative Review.
Review in Journal of clinical medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Prevalence of pharmacologically treated attention deficit hyperactivity disorder in children, adolescents, and adults: systematic review and meta-analysis.Frontiers in psychiatry · 2026Pooled it
- Article
- Regulatory reform and adult methylphenidate dispensing in France: a nationwide interrupted time-series study.BMJ mental health · 2026Article
- Real-World Evidence on Short-Term Weight Changes Following Methylphenidate Use in Pediatric Population: A Retrospective Study Using Common Data Model.Clinical and translational science · 2026Article
- ADHD: Beyond Core Symptoms and Specialist Care.Journal of clinical medicine · 2026Article
- Article
- ADHD in Children, Adolescents, and Adults: Incidence, Prevalence, and Treatment. An Analysis of Routine Health Insurance Data.Deutsches Arzteblatt international · 2026Article
- County-level variation and trajectories in ADHD medication dispensing among Norwegian children and adolescents, 2005-2022: a nationwide prescription register study.Frontiers in psychiatry · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Attention-deficit/hyperactivity disorder (ADHD) is a neurodevelopmental condition frequently treated with pharmacological interventions, most commonly stimulants such as methylphenidate and amphetamines, alongside non-stimulant options. This narrative review, based on 31 publications and five national drug utilization registers, summarizes global trends in ADHD medication use since 2000. Across most countries, prevalence of ADHD medication use increased steadily, with the sole exception of the Netherlands, where recent declines were observed. The highest prevalence of ADHD medication use was consistently found among older children and adolescents. While boys showed higher values of prevalence of ADHD medication use than girls in childhood, faster increases among females resulted in reversed gender ratios in several adult populations. Methylphenidate remained the most widely prescribed drug, although the use of lisdexamfetamine and guanfacine has expanded in recent years. Variations in national guidelines, diagnostic frameworks, healthcare access, and sociocultural acceptance of pharmacotherapy contributed to observed differences across regions. Increasing use of ADHD medications raises important questions about equitable access to treatment, potential overdiagnosis, and the risk of stimulant misuse. These findings highlight the need for continued monitoring of utilization patterns to ensure safe, rational, and equitable ADHD care worldwide.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.